In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-16 of 16 for your search:

Drug:  edrecolomab
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase II/III Randomized Trial of Immunotherapy with MoAb 17-1A Given Before vs After Chemotherapy with FAM (5-FU/ADR/MITO-C) in Patients with Advanced Pancreatic Carcinoma

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: FCCC-85719, NCI-V85-0077

Phase III Randomized Study of Adjuvant MOAB 17-1A plus 5-FU-Based Chemotherapy vs 5-FU-Based Chemotherapy Alone for Surgically Resected Stage III Adenocarcinoma of the Colon (Summary Last Modified 08/1999)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GW-157-001, NCI-V96-0836

Monoclonal Antibody Therapy Compared With No Further Therapy After Surgery in Treating Patients With Stage II Colon Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065473, U10CA031946, CLB-9581, CAN-NCIC-CO14, E-C9581, EORTC-40991, NCCTG-C9581, SWOG-C9581, C9581, CO14, NCT00002968

Phase III Randomized Pilot Study of Adjuvant Immunotherapy with Murine Monoclonal Antibody vs No Adjuvant Therapy in Patients with Colon Carcinoma (Summary Last Modified 05/88)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: NEDH-85999, NCI-V87-0253

Phase I/II Study of Recombinant IL-2 Administered in Conjunction with Antitumor MoAb 17-1A in Patients with Colorectal Cancer Metastatic to the Liver (Summary Last Modified 01/89)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-88-C-64A, NCI-T88-0087N, T88-0087

Phase II Study of MOAB 17-1A/GM-CSF for 5-FU-Resistant Metastatic Colorectal Cancer (Summary Last Modified 02/2001)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GWCC-5095, NCI-V95-0686, NCT00002664

Phase II Immunotherapy with Monoclonal Antibody 17-1A in Patients with Nonresectable Carcinoma of the Pancreas (Summary Last Modified 08/97)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-84-C-231A, NCI-T84-0539N, T84-0539

Phase II Immunotherapy with Recombinant Gamma Interferon plus Murine Monoclonal Antibody 17-1A in Patients with Colorectal Carcinoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: FCCC-86777, NCI-T86-0044D, T86-0044

Phase II Immunotherapy with Monoclonal Antibody 17-1A Following Pretreatment with Gamma-Interferon in Patients with Metastatic or Localized Adenocarcinoma of the Exocrine Pancreas (Summary Last Modified 09/88)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: NCI
Protocol IDs: UNMC-08786, NCI-T86-0050O, T86-0050

10.

Phase II Immunotherapy with Gamma Interferon and 17-1A Monoclonal Antibody in Patients with Metastatic Colon Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UAB-226, NCI-T86-0088D, T86-0088

11.

Phase II Randomized Study of Immunotherapy with IFN-gamma Followed by MoAb 17-1A and IFN-gamma Followed by Peripheral Blood Mononuclear Cells Primed Ex Vivo with MoAb 17-1A in Patients with Advanced Colorectal Carcinoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: MICH-1785, NCI-B86-0002C

12.

Phase II Study of Murine Monoclonal Antibody 17-1A in Patients with Advanced Adenocarcinoma of the Pancreas (Summary Last Modified 03/89)

Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: EST-PZ-288, UNMC-CO-IT-001, EST-P-Z288

13.

Phase II Study of Murine Monoclonal Antibody 17-1A in Patients with Metastatic Colorectal Cancer (Summary Last Modified 01/89)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: UPCC-3288, NCI-V88-0604

14.

Phase I Pilot Evaluation of the Effect of Pretreatment with Recombinant Gamma Interferon on the Response of Patients with Advanced Gastrointestinal Adenocarcinoma to Murine Monoclonal Antibody Therapy

Phase: Phase I
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: FCCC-85742, NCI-T85-0129D, T85-0129

15.

Phase I Pilot Study of Immunotherapy with 17-1A IgG2A Monoclonal Antibody in Patients with Advanced Colorectal and Pancreatic Cancer

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: EST-PZ-286

16.

Adjuvant Immunotherapy with Murine Monoclonal Antibody 17-1A for Resected Dukes Stage C2 and C3 Adenocarcinoma of the Colon and Rectum and Resectable Hepatic Metastases

Phase: No phase specified
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor:
Protocol IDs: NEDH-8603, NCI-V85-0072

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®